Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian C Marschner

Showing results (21-30 of 57) with videos related to

Pageof 6
Sort By:
Statistics in Medicine|October 12, 2005
Missing data methods for the assessment of surrogate outcomes and treatment mechanisms in clinical trial substudiesSally Galbraith, Ian C Marschner, John Simes
Statistical Methods in Medical Research|September 6, 2022
Estimation of the treatment effect following a clinical trial that stopped early for benefitIan C Marschner, Manjula Schou, Andrew J Martin
American Journal of Epidemiology|July 24, 2007
Biases in the identification of risk factor thresholds and J-curvesIan C Marschner, R John Simes, Anthony Keech
Research Synthesis Methods|January 5, 2020
Sensitivity analyses assessing the impact of early stopping on systematic reviews: Recommendations for interpreting guidelinesIan C Marschner, Lisa M Askie, I Manjula Schou
BMC Medical Research Methodology|February 28, 2022
Distributional regression in clinical trials: treatment effects on parameters other than the meanGillian Z Heller, Kristy P Robledo, Ian C Marschner
Journal of Clinical Epidemiology|December 25, 2004
The number needed to treat (NNT) can be adjusted for bias when the outcome is measured with errorIan C Marschner, Jonathan Emberson, Les Irwig, et al.
The International Journal of Biostatistics|October 29, 2021
Penalized likelihood estimation of the proportional hazards model for survival data with interval censoringJun Ma, Dominique-Laurent Couturier, Stephane Heritier, et al.
European Journal of Cancer (Oxford, England : 1990)|May 10, 2011
A systematic review and meta-analysis of KRAS status as the determinant of response to anti-EGFR antibodies and the impact of partner chemotherapy in metastatic colorectal cancerBarbara-Ann Adelstein, Timothy A Dobbins, Carole A Harris, et al.
Journal of Cardiology|March 31, 2010
Design and rationale of a study in Asia of atorvastatin pretreatment in patients undergoing percutaneous coronary intervention for non-ST elevation acute coronary syndromesJunBo Ge, Young-Jo Kim, Yang-Soo Jang, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 28, 2002
Baseline predictors of CD4 T-lymphocyte recovery with combination antiretroviral therapyKara K Bennett, Victor G DeGruttola, Ian C Marschner, et al.
Pageof 6

Showing results (21-30 of 57) with videos related to

Sort By:
Pageof 6
Statistics in Medicine|October 12, 2005
Missing data methods for the assessment of surrogate outcomes and treatment mechanisms in clinical trial substudiesSally Galbraith, Ian C Marschner, John Simes
Statistical Methods in Medical Research|September 6, 2022
Estimation of the treatment effect following a clinical trial that stopped early for benefitIan C Marschner, Manjula Schou, Andrew J Martin
American Journal of Epidemiology|July 24, 2007
Biases in the identification of risk factor thresholds and J-curvesIan C Marschner, R John Simes, Anthony Keech
Research Synthesis Methods|January 5, 2020
Sensitivity analyses assessing the impact of early stopping on systematic reviews: Recommendations for interpreting guidelinesIan C Marschner, Lisa M Askie, I Manjula Schou
BMC Medical Research Methodology|February 28, 2022
Distributional regression in clinical trials: treatment effects on parameters other than the meanGillian Z Heller, Kristy P Robledo, Ian C Marschner
Journal of Clinical Epidemiology|December 25, 2004
The number needed to treat (NNT) can be adjusted for bias when the outcome is measured with errorIan C Marschner, Jonathan Emberson, Les Irwig, et al.
The International Journal of Biostatistics|October 29, 2021
Penalized likelihood estimation of the proportional hazards model for survival data with interval censoringJun Ma, Dominique-Laurent Couturier, Stephane Heritier, et al.
European Journal of Cancer (Oxford, England : 1990)|May 10, 2011
A systematic review and meta-analysis of KRAS status as the determinant of response to anti-EGFR antibodies and the impact of partner chemotherapy in metastatic colorectal cancerBarbara-Ann Adelstein, Timothy A Dobbins, Carole A Harris, et al.
Journal of Cardiology|March 31, 2010
Design and rationale of a study in Asia of atorvastatin pretreatment in patients undergoing percutaneous coronary intervention for non-ST elevation acute coronary syndromesJunBo Ge, Young-Jo Kim, Yang-Soo Jang, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 28, 2002
Baseline predictors of CD4 T-lymphocyte recovery with combination antiretroviral therapyKara K Bennett, Victor G DeGruttola, Ian C Marschner, et al.
Pageof 6